Serena Group

Executive Summary

Serena Group is a specialized clinical research organization (CRO) and trial site network exclusively focused on wound care. Founded in 2018 by a leading wound care specialist with over 25 years of experience, the company manages clinical trials from concept to commercialization, emphasizing physician-driven protocol design, transparent processes, and advanced data analytics. By generating evidence for advanced wound care products such as bioengineered skin, dressings, and therapeutic devices, Serena Group addresses a growing market driven by an aging population and rising chronic wound prevalence. Operating as a service provider, the company benefits from increasing demand for specialized CROs that can navigate the unique regulatory and clinical challenges of wound care. While privately held and lacking disclosed financials, Serena Group's niche focus and physician-led approach position it well within the expanding wound care ecosystem. Continued investment in wound care innovation and potential partnerships with device and biotech firms provide avenues for growth, though competition from larger CROs remains a risk.

Upcoming Catalysts (preview)

• Q3 2026FDA Approval or Breakthrough Designation for Key Wound Care Product Trial Managed by Serena Group40% success
• Q1 2027Major Contract Win with a Leading Wound Care or Bioengineering Company50% success
• TBDExpansion of Trial Site Network Through Acquisition or New Partnerships35% success